Aurora Kinase A - Pipeline Review, H2 2019
Aurora Kinase A - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Aurora Kinase A - Pipeline Review, H2 2019'; Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Aurora kinase A also known as serine/threonine-protein kinase 6 is an enzyme that contributes to the regulation of cell cycle progression. It plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. It is required for initial activation of CDK1 at centrosomes and normal axon formation. It phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. It regulates KIF2A tubulin depolymerase activity.
The report 'Aurora Kinase A - Pipeline Review, H2 2019' outlays comprehensive information on the Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 2 and 2 respectively. Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 4 molecules, respectively. Report covers products from therapy areas Oncology which include indications Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastric Cancer, Hepatocellular Carcinoma, Neuroblastoma, Ovarian Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, B-Cell Chronic Lymphocytic Leukemia, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Lung Cancer, Neuroendocrine Tumors, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer and Soft Tissue Sarcoma.
SCOPE
SUMMARY
According to the recently published report 'Aurora Kinase A - Pipeline Review, H2 2019'; Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Aurora kinase A also known as serine/threonine-protein kinase 6 is an enzyme that contributes to the regulation of cell cycle progression. It plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. It is required for initial activation of CDK1 at centrosomes and normal axon formation. It phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. It regulates KIF2A tubulin depolymerase activity.
The report 'Aurora Kinase A - Pipeline Review, H2 2019' outlays comprehensive information on the Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 2 and 2 respectively. Similarly, the universities portfolio in IND/CTA Filed and Preclinical stages comprises 1 and 4 molecules, respectively. Report covers products from therapy areas Oncology which include indications Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastric Cancer, Hepatocellular Carcinoma, Neuroblastoma, Ovarian Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, B-Cell Chronic Lymphocytic Leukemia, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Malignant Pleural Mesothelioma, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Lung Cancer, Neuroendocrine Tumors, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer and Soft Tissue Sarcoma.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)
- The report reviews Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Overview
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Apollo Therapeutics LLC
CASI Pharmaceuticals Inc
Cielo Therapeutics Inc
Eli Lilly and Co
Merck & Co Inc
Millennium Pharmaceuticals Inc
Nanjing Tianyi Bioscience Co Ltd
Nanjing Transthera Biosciences Co Ltd
Taiho Pharmaceutical Co Ltd
Vichem Chemie Research Ltd
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Drug Profiles
alisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APIOEE-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-137690 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
danusertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBPR-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENMD-2076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3295668 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKA and AURKB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKA, EGFR and JAK2 for Gastrointestinal Tract Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Aurora A Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AURKA and AURKB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Aurora Kinase A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-00420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TY-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Dormant Products
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Discontinued Products
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2019: TransThera Biosciences lead product TT-00420 granted Orphan Drug Designation from FDA to treat Cholangiocarcinoma
Oct 02, 2018: Finding new combination therapies for Neuroblastoma
Sep 28, 2018: TransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC
Jun 25, 2018: Combination Therapy May Revive Prospects for Embattled Breast Cancer Drugs
Dec 21, 2017: Sundia Congratulates NHRI for DBPR114 IND Approval in US & Taiwan
Dec 01, 2017: CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer Symposium (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
Sep 07, 2017: CASI Provides Update on its Cancer Drug Candidate, ENMD-2076
May 30, 2017: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma
May 18, 2017: CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer
Apr 14, 2017: CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer
Mar 28, 2017: CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting
Aug 16, 2016: CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma
Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma
May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)
Nov 08, 2015: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Overview
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
Amgen Inc
Apollo Therapeutics LLC
CASI Pharmaceuticals Inc
Cielo Therapeutics Inc
Eli Lilly and Co
Merck & Co Inc
Millennium Pharmaceuticals Inc
Nanjing Tianyi Bioscience Co Ltd
Nanjing Transthera Biosciences Co Ltd
Taiho Pharmaceutical Co Ltd
Vichem Chemie Research Ltd
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Drug Profiles
alisertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APIOEE-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-137690 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
danusertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBPR-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENMD-2076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3295668 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKA and AURKB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKA, EGFR and JAK2 for Gastrointestinal Tract Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Aurora A Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AURKA and AURKB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Aurora Kinase A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-00420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TY-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Dormant Products
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Discontinued Products
Aurora Kinase A (Aurora 2 or Serine/Threonine Protein Kinase 15 or Serine/Threonine Protein Kinase 6 or Serine/Threonine Protein Kinase Aurora A or Aurora/IPL1 Related Kinase 1 or AURKA or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2019: TransThera Biosciences lead product TT-00420 granted Orphan Drug Designation from FDA to treat Cholangiocarcinoma
Oct 02, 2018: Finding new combination therapies for Neuroblastoma
Sep 28, 2018: TransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC
Jun 25, 2018: Combination Therapy May Revive Prospects for Embattled Breast Cancer Drugs
Dec 21, 2017: Sundia Congratulates NHRI for DBPR114 IND Approval in US & Taiwan
Dec 01, 2017: CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer Symposium (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
Sep 07, 2017: CASI Provides Update on its Cancer Drug Candidate, ENMD-2076
May 30, 2017: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma
May 18, 2017: CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer
Apr 14, 2017: CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer
Mar 28, 2017: CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting
Aug 16, 2016: CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma
Jun 01, 2016: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Ovarian Clear Cell Carcinoma
May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)
Nov 08, 2015: Data On Anti-Tumor Activity Of ENMD-2076 In Triple Negative Breast Cancer Animal Models Presented In Poster Session At AACR-NCI-EORTC International Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Apollo Therapeutics LLC, H2 2019
Pipeline by CASI Pharmaceuticals Inc, H2 2019
Pipeline by Cielo Therapeutics Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Millennium Pharmaceuticals Inc, H2 2019
Pipeline by Nanjing Tianyi Bioscience Co Ltd, H2 2019
Pipeline by Nanjing Transthera Biosciences Co Ltd, H2 2019
Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
Pipeline by Vichem Chemie Research Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Dormant Products, H2 2019 (Contd..5), H2 2019
Dormant Products, H2 2019 (Contd..6), H2 2019
Dormant Products, H2 2019 (Contd..7), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Apollo Therapeutics LLC, H2 2019
Pipeline by CASI Pharmaceuticals Inc, H2 2019
Pipeline by Cielo Therapeutics Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Millennium Pharmaceuticals Inc, H2 2019
Pipeline by Nanjing Tianyi Bioscience Co Ltd, H2 2019
Pipeline by Nanjing Transthera Biosciences Co Ltd, H2 2019
Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019
Pipeline by Vichem Chemie Research Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Dormant Products, H2 2019 (Contd..5), H2 2019
Dormant Products, H2 2019 (Contd..6), H2 2019
Dormant Products, H2 2019 (Contd..7), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Amgen Inc
Apollo Therapeutics LLC
CASI Pharmaceuticals Inc
Cielo Therapeutics Inc
Eli Lilly and Co
Merck & Co Inc
Millennium Pharmaceuticals Inc
Nanjing Tianyi Bioscience Co Ltd
Nanjing Transthera Biosciences Co Ltd
Taiho Pharmaceutical Co Ltd
Vichem Chemie Research Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Amgen Inc
Apollo Therapeutics LLC
CASI Pharmaceuticals Inc
Cielo Therapeutics Inc
Eli Lilly and Co
Merck & Co Inc
Millennium Pharmaceuticals Inc
Nanjing Tianyi Bioscience Co Ltd
Nanjing Transthera Biosciences Co Ltd
Taiho Pharmaceutical Co Ltd
Vichem Chemie Research Ltd
